摘要
目的比较糖尿病患者及其他类型肾病患者肾组织中Smad1蛋白表达量的差异,以及与相应尿Smad1蛋白含量的关系。方法收集通过肾活检确诊的糖尿病肾病患者(DN组9例)及其他类型肾病患者,包括局灶性肾小球硬化性肾病(FSGS组5例)、IgA肾病(IgA组12例)、微小病变型肾病(MNP组10例)的尿液及肾活检组织。ELISA以及免疫组化、免疫荧光等方法检测尿Smad1蛋白含量、肾活检组织Smad1蛋白的表达情况以及可受Smad1调节的胶原蛋白4(Col4)、α-平滑肌肌球蛋白(α-SMA)的表达情况。结果DN组及其他3种肾病的患者均检测到尿中有Smad1蛋白的排泄,均高于健康人群(47例)(P<0.05)。4组肾病患者的肾活检组织不同区域(包括肾小球与肾小管区域)均有Smad1蛋白的表达,而DN组肾小管区域的Smad1蛋白的表达含量高于其他3组的水平(P<0.05)。4组肾病患者肾活检组织中不同区域均有Col4、α-SMA蛋白与Smad1蛋白共同表达。结论不同肾病肾组织的不同区域都有Smad1蛋白表达的上调,与肾损伤有关。
Objective To compare urinary Smad1 and the protein content of Smad1 in renal tissues of patients with diabetic nephropathy(DN)and the patients with other types of nephropathy.Methods According to the result of renal biopsy,the patients were collected and divided into four groups as follows:the patients with diabetes nephropathy(DN group,9 cases),with focal segmental glomerulosclerosis(FSGS group,5 cases),with IgA nephropathy(IgA group,12 cases)and with minimal change nephrosis(MNP group,10 cases).Urinary Smad1 was examined using ELISA.The expression of Smad1,Col4 and α-SMA in renal tissues was detected by immunohistochemistry and immunofluorescence staining method.Results Urinary Smad1 can be detected in the DN group and there other groups(FSGS group,IgA group and MNP group).The urinary Smad1 from four groups was higher significantly than those from 47 healthy people with routine physical examination(P<0.05).The expression of Smad1 in different area of the renal tissues(the area of glomerulus and renal tubule)can be observed by immuno-histochemistry staining in the patients with four different types of nephropathy.The Smad1 expression in the renal tissue of the patients with diabetes nephropathy was higher than that of three other groups(P<0.05).The co-expression of Col4 andα-SMA with Smad1 in different area of the renal tissues(the area of glomerulus and renal tubule)was found.Conclusions The over-expression of Smad1 in different area of the renal tissues can be observed and is related with renal damage.
作者
陈纤纤
冯烈
周颖
董向楠
CHEN Xianxian;FENG Lie;ZHOU Ying;DONG Xiangnan(Endocrinological and Metabolic Department,the First Affiliated Hospital of Jinan University,Guangzhou 510632,China;Nephrology Department,the First Affiliated Hospital of Jinan University,Guangzhou 510632,China)
出处
《基础医学与临床》
2023年第7期1097-1103,共7页
Basic and Clinical Medicine
基金
中央高校基本科研业务费专项资金(11617317)。
